We sought to demonstrate the versatility and effectiveness of our polymer carrier system both in vitro and in vivo using the HER2 antibody, trastuzumab, in a solid tumor xenograft model of ovarian cancer. This evidence concerns the gene ERBB2 and ovarian carcinoma.